Elanco Animal Health, Inc. (ELAN)

In July 2025, Elanco received USDA approval for TruCan Ultra CIV H3N2/H3N8 and entered an exclusive licensing agreement with Neurizon Therapeutics, which led to a slight stock decline. In September 2025, Credelio Quattro achieved $100 million in net sales, boosting the stock, and Stifel raised its price target. In October 2025, Elanco received FDA emergency use authorization for Credelio to treat New World screwworm infestations, leading to a stock upgrade by JPMorgan. In November 2025, the FDA granted emergency use authorization for Credelio CAT, and Argus upgraded Elanco's rating. In December 2025, Elanco's Investor Day outlined a growth plan and restructuring initiative, causing a stock decline, and an insider acquired shares. In January 2026, Elanco's stock hit a new 52-week high, and the company participated in the J.P. Morgan Healthcare Conference, with the stock price jumping 64.6% over the past six months.

Elanco Animal Health experiences regional and seasonal fluctuations influenced by weather and pest pressures. A significant portion of revenue for parasiticide products is generated in the first half of the year. There is a rising global demand for animal health products, driven by increasing pet ownership and the growing need for protein and disease prevention in livestock production. Seasonal chart analysis suggests a potential "Buy Date" of September 19 and a "Sell Date" of January 16.

Elanco Animal Health, Inc. operates in the Pharmaceuticals sector, focusing on the animal health industry, innovating, developing, manufacturing, and marketing products and services to prevent and treat diseases in farm animals and pets. The company's product portfolio includes pet health products like parasiticides, vaccines, and therapeutics, and farm animal products such as antibiotics, vaccines, and feed additives for cattle, poultry, swine, and sheep.

Elanco Animal Health has a global presence, supplying products and services to over 90 countries across Asia, Europe, Australia, North America, and the Middle East. The company's global headquarters is located in Greenfield, Indiana, U.S., with plans for a new consolidated global headquarters in downtown Indianapolis.

Elanco's brand reputation has seen positive developments, including a strong stock rebound, successful product launches, and key product approvals. Challenges include the "Elanco Ascend" restructuring plan and competitive pressure from new products. A historical issue involved the Seresto flea and tick collar, which was linked to pet poisoning incidents, but the EPA could not determine if Seresto was the cause of reported animal deaths.

Institutional investors hold 92.3% of Elanco Animal Health's shares, with major holders including Dodge & Cox, Fmr Llc, and Vanguard Group Inc. Scott D. Ferguson is the largest individual shareholder, owning 5.60% of the company, while insiders collectively own 0.89% of the stock.